[Federal Register Volume 63, Number 19 (Thursday, January 29, 1998)]
[Notices]
[Pages 4454-4455]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-2163]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[INFO-98-10]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) and the Agency for Toxic Substances and Disease
Registry (ATSDR) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call the CDC/ATSDR
Reports Clearance Officer on (404) 639-7090.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques for other
forms of information technology. Send comments to Wilma Johnson, CDC/
ATSDR Reports Clearance Officer, 1600 Clifton Road, MS-D24, Atlanta, GA
30333. Written comments should be received within 60 days of this
notice.
Proposed Projects
1. Project Intensive Care Antimicrobial Resistance Epidemiology
(ICARE), Phase 3--Reinstatement--The Hospital Infections Program,
National Center for Infectious Diseases, Centers for Disease Control
and Prevention, is proposing a study to investigate the
[[Page 4455]]
relationship between use of antimicrobial agents and the incidence of
antimicrobial resistance at 40 U.S. hospitals. The proposed Phase 3
study of Project ICARE will be very similar to Phase 2 ICARE with minor
revisions. We hope to enroll 40 hospitals and address many confounding
factors of antimicrobial resistance. In addition, these hospitals will
serve as a sentinel surveillance system for different antimicrobial
resistant pathogens, such as vancomycin resistant staphylococci. About
half of the hospitals have participated in Phase 2 of Project ICARE.
Participating hospitals will all be active participants of the CDC's
National Nosocomial Infections Surveillance (NNIS) system. Phase 3 of
Project ICARE is a refinement of the Phase 2 study and will allow
interhospital comparison of data (i.e., sending interim reports back to
study hospitals) facilitated by incorporating differences in culturing
frequency, case-mix by ICU type and speciality wards (i.e., internal
organization), barrier precautions, and prescribing practice policies.
Phase 3 will also allow for valid comparison of attempts at reducing
antimicrobial resistance in study hospitals (i.e., publish results of
interventions to reduce antimicrobials resistance at study hospitals).
Also, key parameters of antimicrobial use could be correlated with
antimicrobial resistance levels and tracked through the hospital's
quality improvement indicator process, pharmacy and therapeutics
committee, or medical staff. Unnecessary use of antimicrobials may be
reduced by these efforts if the information can be provided to
hospitals. Average cost to respondents is $17.18.
----------------------------------------------------------------------------------------------------------------
Average
Number of burden/ Total
Form name respondents Number responses/respondent response (in burden (in
hours) hours)
----------------------------------------------------------------------------------------------------------------
Primary contact........................... 40 12.......................... 1 480
Pharmacy.................................. 40 48 (median)................. 2.0 3,840
Microbiology.............................. 40 60 (median)................. 0.5 1,200
Isolates.................................. 40 80 (maximum)................ 0.20 640
---------------------------------------------------------------------
Total............................... ........... ............................ ............ 6,160
----------------------------------------------------------------------------------------------------------------
Dated: January 23, 1998.
Charles Gollmar,
Acting Associate Director for Policy Planning And Evaluation, Centers
for Disease Control and Prevention (CDC).
[FR Doc. 98-2163 Filed 1-28-98; 8:45 am]
BILLING CODE 4163-18-P
